"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010879
|
| MeSH Number(s) |
D03.383.606
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 3 | 0 | 3 |
| 2002 | 6 | 2 | 8 |
| 2003 | 11 | 5 | 16 |
| 2004 | 6 | 6 | 12 |
| 2005 | 4 | 7 | 11 |
| 2006 | 2 | 5 | 7 |
| 2007 | 8 | 2 | 10 |
| 2008 | 5 | 5 | 10 |
| 2009 | 7 | 8 | 15 |
| 2010 | 9 | 6 | 15 |
| 2011 | 10 | 7 | 17 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 4 | 9 |
| 2014 | 4 | 2 | 6 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 3 | 5 |
| 2017 | 6 | 2 | 8 |
| 2018 | 3 | 4 | 7 |
| 2019 | 5 | 5 | 10 |
| 2020 | 3 | 2 | 5 |
| 2021 | 6 | 5 | 11 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperazines" by people in Profiles.
-
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct; 8:e2400477.
-
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Oct 01; 30(19):4318-4328.
-
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul; 8:e2400219.
-
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 Jun 07; 26(1):95.
-
Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness. Cell Death Dis. 2024 May 28; 15(5):370.
-
Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy. Adv Sci (Weinh). 2024 Jun; 11(23):e2310309.
-
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):265-270.
-
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 Apr 15; 130(8):1234-1245.
-
Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan. Value Health Reg Issues. 2022 Sep; 31:34-38.
-
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 07; 11(14):2790-2800.